Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic MarkersAndré Oberthuer, Matthias Fischer, Andreas Faldum et al.|Clinical Cancer Research|2014Cited by 99
CDK4 overexpression is a predictive biomarker for resistance to conventional chemotherapy in patients with osteosarcomaShintaro Iwata, Miki Ohira|Oncology Reports|2021Cited by 25
Supplementary Data 1 from Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic MarkersAndré Oberthuer, Matthias Fischer, Dilafruz Juraeva et al.|Unknown|2023Cited by 0